Radical immune cell therapy tested as last hope for devastating autoimmune diseases
NCT ID NCT06688799
Summary
This early-phase study is testing a therapy called CD19 CAR T-cells in people with severe autoimmune diseases that have not improved with standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to target a specific marker (CD19), and infusing them back to potentially reset the faulty immune system. The main goals are to find a safe dose and see if the treatment can effectively control these difficult diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, China, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.